CD180 Overexpression in Follicular Lymphoma

Follicular Lymphoma Clinical Trial

Official title:

CD180 Overexpression in Follicular Lymphoma Is Restricted to the Lymph Node Compartment

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02978898
• Other study ID #: 69HCL16_0564
• Status: Completed
• Phase: N/A
• First received: August 29, 2016
• Last updated: November 29, 2016
• Start date: June 2012
• Est. completion date: June 2015

Study information

• Verified date: August 2016
• Source: Hospices Civils de Lyon
• Contact: n/a
• Is FDA regulated: No
• Health authority: France: The Commission nationale de l’informatique et des libertés
• Study type: Observational

Clinical Trial Summary

Background:Altered Toll-like receptor (TLR) expression levels and/or mutations in its signaling pathway (such as MyD88 mutation) contribute to the pathogenesis of lymphoproliferative disorders (LPD). CD180 is an orphan member of the TLR family that modulates the signaling of several TLRs, but only limited studies have evaluated its expression by flow cytometry (FCM) in LPD.

Methods: Using a multiparameter FCM approach, biologists have assessed CD180 mean fluorescence intensity (MFI) in lymph nodes (LNs) and peripheral blood (PB) samples obtained from patients with follicular lymphoma (FL; LN/PB, n=44/n=15), chronic lymphocytic leukemia (CLL, n=26/n=21), mantle cell lymphoma (MCL, n=13/n=17), and marginal zone lymphoma (MZL, n=16/n=12). Specimens from non-tumoral PB and LN (n=8/n=12) were used as controls.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 184
• Est. completion date: June 2015
• Est. primary completion date: June 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Samples from patients with:

• LF: Follicular lymphoma

• MCL: Mantle cell lymphoma

• CLL/SLL: chronic lymphocytic leukemia/small lymphocytic leukemia

• MZL : splenic marginal zone

• Clt :control B-cells

Exclusion Criteria:

• Patient <18 years old

Study Design

Observational Model: Cohort, Time Perspective: Retrospective

Related Conditions & MeSH terms

• Follicular Lymphoma
• Lymphoma
• Lymphoma, Follicular

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Hospices Civils de Lyon

References & Publications (1)

Mestrallet F, Sujobert P, Sarkozy C, Traverse-Glehen A, Callet-Bauchu E, Magaud JP, Salles G, Baseggio L. CD180 overexpression in follicular lymphoma is restricted to the lymph node compartment. Cytometry B Clin Cytom. 2016 Sep;90(5):433-9. doi: 10.1002/c — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Immunophenotype Analysis by Flow Cytometry of lymph nodes samples at inclusion	Using a multiparameter FCM approach, biologists assessed the CD180 expression by our routine antigen panel in LN suspensions as well as in PB samples. Samples were analyzed on a BD FACSCanto II cytometer (BD FACS DIVA software; Becton Dickinson, San Jose, CA).	At inclusion, day 0.	No
Primary	Immunophenotype Analysis by Flow Cytometry of peripheral blood samples at inclusion	Using a multiparameter FCM approach, biologists assessed the CD180 expression by our routine antigen panel in LN suspensions as well as in PB samples. Samples were analyzed on a BD FACSCanto II cytometer (BD FACS DIVA software; Becton Dickinson, San Jose, CA).	At inclusion, day 0.	No